Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study) ; volume:23 ; number:1 ; day:31 ; month:5 ; year:2023 ; pages:1-10 ; date:12.2023
BMC psychiatry ; 23, Heft 1 (31.5.2023), 1-10, 12.2023
- Urheber
-
Oluboka, Oloruntoba
Clerzius, Guerline
Janetzky, Wolfgang
Schöttle, Daniel
Therrien, François
Wiedemann, Klaus
Roy, Marc-André
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12888-023-04893-8
- URN
-
urn:nbn:de:101:1-2023091209095408049465
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Oluboka, Oloruntoba
- Clerzius, Guerline
- Janetzky, Wolfgang
- Schöttle, Daniel
- Therrien, François
- Wiedemann, Klaus
- Roy, Marc-André
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)
Learn Once - Write Anywhere with React
Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study
React: recognize every action everywhere all at once
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
Treatment persistence with aripiprazole once monthly: a 4-year follow-up
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study
Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)
Learn Once - Write Anywhere with React
Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study
React: recognize every action everywhere all at once
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
Treatment persistence with aripiprazole once monthly: a 4-year follow-up
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study
Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)
Learn Once - Write Anywhere with React
Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study
React: recognize every action everywhere all at once
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
Treatment persistence with aripiprazole once monthly: a 4-year follow-up
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study